EIKN
Eikon Therapeutics, Inc.
7.30$
-1.1%
vs. previous close
Closing price · As of: Oct 2, 2026
Statements
Cash Flow
All figures as the change versus the prior period, in percent. Periods without a positive comparison base stay empty.
Tick rows to compare them in a chart (up to 4)
| Line item | Q4 24 | Q1 25 | Q2 25 | Q3 25 | Q4 25 | Q1 26 | Q2 26 | LTM* |
|---|---|---|---|---|---|---|---|---|
| – | – | – | – | – | – | – | – | |
| – | +4.0% | -2.4% | -0.2% | -18.9% | +0.2% | -1.6% | – | |
| – | -6.6% | +142.9% | -44.7% | -3.3% | -28.1% | +51.9% | – | |
| – | -83.4% | +624.4% | -93.2% | +992.5% | -146.9% | – | – | |
| – | -43.4% | -2.9% | -88.0% | -97.5% | +297.0% | -4.2% | – | |
| – | – | – | – | +47.1% | -599.2% | – | – | |
| – | +368,567.4% | -99.9% | -59.3% | +416.1% | +31,976.0% | -100.0% | – | |
| – | – | -183.2% | – | – | +74,904.0% | -133.0% | – | |
| – | – | – | – | – | – | – | – |
LTM = last twelve months (sum of the four most recent quarters).
Data as of: October 2, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.